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Abstract
AQ2
Type 2 diabetes mellitus (T2DM) has growing prevalence worldwide
and major clinical implications, chiefly cardiovascular (CV) and renal
disease burden. Sodium-glucose co-transporter (SGLT)2 inhibitors are a
new drug class in the management of T2DM with a mechanism of action
independent of insulin. In addition to their hypoglycaemic effect,
SGLT2 inhibitors appear to have haemodynamic and nephroprotective
effects. Studies have consistently showed a modest but significant blood
pressure (BP) reduction. Metabolic benefits are also attributed to SGLT2
inhibitors with a modest but consistent body weight decrease recorded
along with improvements in lipid profile and uric acid levels.
Remarkable findings of significant cardioprotective effects came from
the recent EMPA-REG study with a particular focus on heart failure. In
the kidney, SGLT2 inhibitors reduce hyperfiltration, a precipitant of
diabetic nephropathy.
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ABPM Ambulatory blood pressure monitoring
ACR Albumin to creatinine ratio
BP Blood pressure
CKD Chronic kidney disease
CV Cardiovascular
DBP Diastolic blood pressure
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GFR Glomerular filtration rate
HCZT Hydrochlorothiazide
HDL High density lipoprotein
HR Hazard ratio
LDL Low density lipoprotein
OD Once daily
RAAS Renin-aldosterone-angiotensin system
SGLT Sodium-glucose co-transporter
SBP Systolic blood pressure
TG Triglycerides
TGF Tubuloglomerular feedback
VLDL Very low density lipoprotein
Introduction
Sodium-glucose co-transporter (SGLT)2 inhibitors constitute a newly
employed drug class in the management of type 2 diabetes mellitus
(T2DM). Their mechanism of action differs from all other hypoglycaemic
agents as they do not rely upon insulin secretion or sensitivity for glucose
regulation, but instead promote urinary glucose excretion.
SGLT2 is a low-affinity, high-capacity, Na /glucose co-transporter
expressed on the luminal surface of proximal tubular cells in S1 and S2
segments, which mediates the reabsorption of 80–90% of filtered glucose
(Fig. 1 ) [ 1 ]. SGLT1 is also expressed to a far smaller degree in S3
segment of proximal tubule, but contributes less than 10% of tubular
glucose reabsorption [ 2 ]. In addition to the SGLT2 transport system in the
kidney, SGLT1 in the intestine also acts to increase glucose reabsorption.
Most SGLT2 inhibitors have no significant effect on SGLT1, but
canagliflozin does affect SGLT1. For this reason, data of the performance
of SGLT2 inhibitors have been presented in this review at a drug level,
rather than class level.
Fig. 1
Schematic representation of SGLT2 inhibitors action in the kidney. SGLT2
are expressed in the S1 segment of the proximal tubule. More than 90% of
+
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filtered glucose is reabsorbed there. SGLT2 inhibitors block glucose
reabsorption with resultant glucosuria
Evidence suggests that SGLT2 inhibitors are potent antihyperglycaemic
agents with a low risk of hypoglycaemia, comparable to that of metformin
and sitagliptin [ 3 ]. A recent meta-analysis suggested a small benefit of
high-dose canagliflozin monotherapy in glucose lowering over other
SGLT2 inhibitors [ 4 ]; whether this is related to canagliflozin dual
mechanism of action on both SGLT1 and SGLT2 remains unclear. As
previously mentioned, the striking difference to other antidiabetic
medications is that their mechanism of action is insulin-independent.
However, a mode of action that is reliant upon glomerular filtration means
that efficacy is diminished in patients with renal impairment. Therefore,
current SGLT2 inhibitors: canagliflozin, dapagliflozin and empagliflozin,
are licensed for the management of diabetes in patients if estimated
glomerular filtration rate (eGFR) is greater than 45 mls/min. As SGLT2
inhibitors promote glycosuria, intuitively, there will be attendant fluid
shifts through osmotic drag. It is therefore unsurprising that SGLT2
inhibitors have effects on the cardio-renal system independent of that of
glucose lowering.
This review will highlight recent data derived from randomized, double-
blind, placebo-controlled, phase III trials, with a focus on their non-
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hypoglycaemic effect on the cardiometabolic profile (Fig. 2 ). Possible
underlying mechanisms will also be discussed.
Fig. 2
Overview of the actions of SGLT2 inhibitors and secondary effects leading
to improved cardiovascular outcomes. SGLT2 inhibitors act in the proximal
renal tubule causing glycosuria, natriuresis and osmotic diuresis. Thereafter,
a series of hemodynamic, metabolic and nephroprotective effects are
induced, leading eventually to improved cardiovascular outcomes
Blood Pressure Effects
One of the most prominent, non-hypoglycaemic effect of SGLT2 inhibitors
is their blood pressure (BP) lowering action, which has been broadly
recorded in large and smaller trials (Tables 1  and 2 )
[ 5, 6, 7, 9, 10, 12, 13, 17, 18, 19, 20, 21 ].
Table 1
Summary of randomised placebo-controlled trials comparing SGLT2 inhibitor monotherapy to
placebo
AQ5
Studies Intervention Population Number
Follow
up
(weeks)
Effects* p value
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Stenlof et
al. [ 5 ]
Canagliflozin
100 or 300 mg
OD
T2DM not
controlled on
diet and
exercise/other
AHA
587 26
•↓TBW
• ↓SBP
• ↑HDL
p < 0.001
for all
Ferrannini
et al. [ 6 ]
Dapagliflozin
2.5, 5 or 10
OD
T2DM not
controlled on
diet and
exercise
587 24 • ↓TBW• ↓BP
p NS for
both
Seino et
al. [ 7 ]
Luseogliflozin
2.5 mg OD
T2DM not
controlled on
diet and
exercise
158 24 • ↓TBW• ↓ WC
p < 0.05
for both
Bode et
al. [ 8 ]
Canagliflozin
100 or 300 mg
OD
Older (55–
80 years)
with T2DM
not controlled
on other
AHA
716 26
• ↓TBW
• ↓SBP
• ↑HDL
• ↑LDL
p < 0.001
for all
Kaku et
al. [ 9 ]
Dapagliflozin
5 or 10 mg
OD
T2DM not
controlled on
diet and
exercise
261 24 • ↓TBW• ↓ BP
p = 0.0001
to 0.0003
p NS
Inagaki
[ 10 ]
Canagliflozin
100 or 200 mg
OD
T2DM
inadequately
controlled on
diet and
exercise
272 24 • ↓TBW• ↓ BP
p < 0.05
p < 0.05
Inagaki et
al. [ 11 ]
Canagliflozin
100 mg OD
T2DM not
controlled on
insulin, diet
and exercise
146 16
• ↓TBW
• ↓ SBP
• ↑HDL
p < 0.001
p = 0.058
p = 0.007
Summary of main characteristics and non-hypoglycaemic effects of randomised placebo-
controlled trials comparing SGLT2 inhibitor monotherapy to placebo
AHA anti-hypoglycaemic agent, T2DM type 2 diabetes mellitus, TBW total body weight,
TC waist circumference, FM fat mass, BP blood pressure, HDL high density lipoprotein
*Only findings provided by direct comparisons of drug effects with placebo have been
included
Table 2
Summary of randomised placebo-controlled trials comparing SGLT2 inhibitor combined with
metformin to placebo
Investigators Intervention Population Number
Follow
up
(weeks)
Effects* p value
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Bailey et al.
[ 12 ]
Dapagliflozin
2.5, 5 or
10 mg
T2DM not
controlled on
metformin
(≥1500 mg/day)
534 24 • ↓TBW p < 0.001
Haring et al.
[ 13 ]
Empagliflozin
10 or 25 mg
T2DM not
controlled on
metformin
(≥1500 mg/day)
637 24 • ↓TBW• ↓BP
p < 0.001
p < 0.001
to 0.26
Lavalle-
Gonzalez et
al. [ 14 ]
Canagliflozin
100 or
300 mg
T2DM not
controlled on
metformin
(≥1500 mg/day)
1284 26 wks • ↓TBW• ↓SBP
p < 0.001
p < 0.001
Bolinder et
al. [ 15 ]
Dapagliflozin
10 mg
T2DM not
controlled on
metformin
(≥1500 mg/day))
182 24
• ↓TBW
• ↓ WC
• ↓ FM
↓ BP
p < 0.001
p = 0.014
p < 0.001
NS
Kashiwagi et
al. [ 16 ]
Ipragliflozin
50 mg
T2DM not
controlled on
metformin
(≥1500 mg/day)
168 24
• ↓TBW
• ↓ WC
• ↑HDL
p < 0.001
p = 0.001
p = 0.006
Summary of main characteristics and non-hypoglycaemic effects of randomised placebo-
controlled trials comparing SGLT2 inhibitor combined with metformin to placebo
*Only findings provided by direct comparisons of drug effects with placebo have been
included
T2DM type 2 diabetes mellitus, TBW total body weight, TC waist circumference, FM fat mass,
BP blood pressure, HDL high density lipoprotein
A recent meta-analysis of 13 trials by Shyangdan et al. [ 4 ] indicated that
all SGLT2 inhibitors given as monotherapy or combined with other
antidiabetic agents—usually metformin—led to a reduction in systolic BP
(SBP) compared with placebo; reductions from baseline ranged from
2.6 mmHg with empagliflozin (10 mg once daily (OD)) to 6 mmHg with
canagliflozin (300 mg OD). The authors also suggested that dapagliflozin
10 mg might be superior in reducing SBP compared to canagliflozin,
empagliflozin and ipragliflozin. Similarly, a previous meta-analysis had
shown that SGLT2 inhibitors are significantly more effective compared to
both placebo and other antihyperglycaemic agents in reducing SBP (mean
difference, −3.77 and −4.45 mmHg, respectively) and diastolic BP (DBP)
(mean difference −1.75 and 2.01, respectively) [ 22 ]. These came to
confirm earlier findings of Baker et al. [ 23 ], who also noted that BP-
lowering action of SGLT2 inhibitors was not dependent on baseline BP
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levels and reductions were not associated with any changes in heart rate or
body weight. Baker et al. also highlighted a dose-related SBP lowering
effect of canagliflozin.
In patients with T2DM and poorly controlled hypertension on
antihypertensive agents, at baseline BP, changes have been assessed with
24-h ambulatory BP monitoring (ABPM). Canagliflozin, 300 mg, led to an
early (6 weeks) and significantly greater reduction in mean 24-h SBP and
DBP compared to placebo (p = 0.006 for both) [ 21 ]. Similar findings were
noted with empagliflozin 10 or 25 mg with greater reductions in mean 24-h
SBP and DBP (p < 0.001 vs placebo for both doses) at week 12 [ 18 ]. The
differences were more pronounced for patients who had a 24-h mean
ABPM >130/80 mmHg at baseline. In both studies, the effect, though
present, was less prominent on night-time BP suggesting an agreement to
circadian BP rhythm. Importantly, the reductions in BP were not
accompanied by increases in heart rate.
In a similar population, dapagliflozin led to more pronounced reductions in
mean seated and 24-h SBP compared to placebo [ 24 ]. A post hoc analysis
showed that the mean change in seated SBP related to dapagliflozin was
greater in patient groups on beta-blockers or calcium channel inhibitors
than those on thiazides, but meaningful reductions were noted in all
groups.
The underlying physiology of SGLT2 inhibitor effects on BP is thought to
involve more than one mechanism; osmotic diuresis and urinary sodium
excretion have been considered the principal mechanisms. Though data are
limited, it appears that plasma volume decreases with dapagliflozin
treatment when compared with placebo or, more interestingly, with
hydrochlorothiazide (HCTZ) [ 25 ]. In another study, the addition of
canagliflozin to HCTZ in healthy individuals did not confer further change
in urine volume, Na excretion, or BP [ 26 ]. This discrepancy of SGLT2
inhibition effect on volume between diabetic and non-diabetic individuals
most likely reflects the significance of sodium excretion and reduction of
total body sodium content over a mere diuretic effect. Patients with
diabetes have an increased total exchangeable sodium content compared to
non-diabetic individuals [ 27 ]. Moreover, the absence of changes in heart
rate accompanying BP reductions is suggestive of euvolaemia rather than
volume depletion, highlighting the importance of total body sodium
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content as a principal pathophysiologic mechanism in diabetic
hypertension.
The result of SGLT2 inhibition highly depends on serum glucose levels
with the expression of SGLT2 in the proximal tubule to increase under
conditions of hyperglycaemia [ 28 ]. In this context, it might prove useful
to assess whether BP-lowering efficacy of SGLT2 inhibitors varies
according to levels of HbA1C. The fact that dapagliflozin showed a more
pronounced SBP reduction when added to beta-blockers or calcium
channel blockers, compared to thiazides [ 24 ], does not come as a surprise,
indicating the role of volume contraction in SGLT2 inhibitor
antihypertensive effect. The aforementioned mechanisms supposedly
mediating BP-lowering effect are physiologically related to eGFR;
therefore the magnitude of SGLT2 inhibitor antihypertensive effect should
vary according to GFR; subgroup analyses in trials can shed more light.
Less direct effects, associated with SGLT2 inhibitor-induced weight loss
(discussed below) may contribute. Even modest weight reductions are
associated with a beneficial effect on BP [ 29 ]. However, given that the
effect on BP is evident early in treatment period, body weight reduction
cannot primarily account for this effect. Modification of arterial stiffness
has been considered as another mechanism implicated in SGLT2 inhibitors
antihypertensive effect, based on findings of reduced arterial stiffness
associated with SGLT2 inhibition in young type-1 diabetic patients [ 30 ].
Given the complex causal relationship between hypertension and arterial
stiffness [ 31 ], it is unclear to what extent the BP-lowering effect of
SGLT2 inhibitors may follow or actually precede an improvement in
vascular properties (Table 3 ).
Table 3
Main advantages and disadvantages of SGLT2 inhibitors
Advantages Disadvantages
Glucose lowering independent of
insulin Risk of acute kidney injury
Reduction of body weight and visceral
adiposity Risk of urinary and genital infections
Reduction of blood pressure Indicated only foreGFR ≥ 45 ml/min/1.73 m
Risk of euglycaemic ketoacidosis
2
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Improvement of lipid profile (rare)
Nephroprotection  
Improved cardiovascular outcomes  
AQ6
Metabolic Effects
SGLT2 inhibition is associated with a series of interrelated metabolic
effects, primarily represented by amelioration of adverse lipid profile and
body weight reductions. Effects on visceral adiposity and hepatic liver
content have also been reported (Tables 1  and 2 ).
Lipid Effects
The majority of individuals with T2DM have underlying insulin resistance
and the metabolic syndrome. This is associated with a dyslipidaemic
pattern of hypertriglyceridaemia, low high density lipoprotein (HDL) and a
predominance of small, dense (pro-atherogenic) low density lipoprotein
(LDL). The mechanism underlying this is thought to be due to
overproduction of very low density lipoprotein (VLDL) by the liver,
leading to an increased plasma concentration of triglycerides (TG)
[ 32, 33 ] which, via an exchange process mediated by cholesterol-ester
transfer protein (CETP), results in a low concentration of HDL-cholesterol
as well as the generation of small, dense, cholesterol-ester-depleted LDL.
It has been shown that moderate restriction of carbohydrate leads to
benefits in weight loss and improvement in the lipid profile of the
metabolic syndrome [ 34 ].
As would be predicted from dietary studies of carbohydrate restriction, the
SGLT2 inhibitors also lead to reduction of TG and an increase in HDL
[ 5, 9, 12, 16, 17, 20, 35 ]. It has been proposed that the changes in TG and
HDL-cholesterol with SGLT2 inhibition are purely a consequence of
weight reduction [ 36 ]. However, it may be that a reduction in
carbohydrate (due to renal losses of glucose) will also reduce plasma TG
by reducing hepatic VLDL production.
SGLT2 inhibitors have been consistently associated with an increase in
LDL-cholesterol, by up to 10%, which appears to be a class-effect of these
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agents [ 12, 35, 37 ]. Although meta-analyses of pre-clinical data have
shown, no adverse cardiovascular (CV) effects [ 38 ], in light of the
experience relating to CV disease and rosiglitazone [ 39 ], it is imperative
that we fully understand the effect on CV disease risk of novel treatments
for dysglycaemia. Specifically in this case, how SGLT2 inhibitors
influence structural properties of LDL-cholesterol that relate to its
atherogenic potential.
Body Weight and Fat Tissue
Obesity, and more particularly central adiposity, is strongly associated
with impaired glucose metabolism and an adverse metabolic profile.
SGLT2 inhibitors reportedly reduce body weight with preferential effect
on adipose tissue.
Several SGLT inhibitors such as canagliflozin, dapagliflozin,
luseogliflozin, or tofogliflozin, either as monotherapy or combined with
metformin, achieved statistically significant reductions in body weight
compared to placebo in RCTs with a consistent dose-related effect and
mean difference from placebo ranging from 1.61 kg at lower doses to 2.66
at maximum doses [ 8, 9, 10, 11, 14, 15, 17, 20, 40 ], frequently followed by
a reduction in waist circumference [ 7, 15, 16, 40 ]. This favourable effect
has also been recorded in a study of 638 patients randomised to receive
empagliflozin (10 or 25 mg OD) or placebo as an add-on to metformin
(1500 mg/day) [ 13 ].
Visceral adiposity, which is known to be related with an adverse metabolic
profile, is likely principally affected. In an RCT which compared
dapagliflozin vs placebo as an add-on to metformin, dapagliflozin caused
greater reduction in waist circumference at 24 weeks which increased
further after 2 years of treatment [ 15, 40 ]. The overall weight loss
recorded was mainly attributed to adipose tissue loss rather than lean mass
as suggested by dual-energy x-ray absorptiometry.
There is much interest in the observation in longer-term clinical trials,
whether weight loss observed can be fully explained by glycosuria. For
instance, canagliflozin led to a dose-related effect on body weight with
mean reductions by 2.2% (1.9 kg) and 3.3% (2.9 kg) after 6 months of
treatment at 100 and 300 mg, respectively [ 5 ]. The change in body weight
was more pronounced over the first 6 weeks of treatment. This may
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suggest that patients ‘compensate’ in the long term by increasing calorie
intake. However, it may be that standard models to predict weight loss are
inadequate. In addition, the metabolic effect of energy restriction is
dependent upon baseline weight and adiposity. Individuals with a higher
baseline weight and adiposity tend to partition a greater proportion of net
energy imbalance towards loss of fat. The energy contents of fat and
skeletal muscle are very different with five times more energy required to
mobilise 1 kg of fat than lean tissue. Furthermore, lean tissue contributes
more than fat tissue to total energy expenditure and when it is lost over fat
mass, energy expenditure decreases to a greater extent, making further
weight loss become more difficult. In this way, weight loss against time
may be thought of as curvilinear rather than linear.
The degree of weight loss reported with SGLT2 inhibitor treatment may be
considered as insignificant in an obese individual. However, dietary studies
have shown that visceral adipose tissue is lost preferentially in the setting
of modest weight loss [ 41 ]. Reduction of 5% in body mass index has been
shown to decrease liver fat content, measured by magnetic resonance
spectroscopy (MRS), by 25.5% [ 42, 21 ]. Moreover, reduction of hepatic
fat content can lead to favourable changes in the lipoprotein profile [ 43 ],
which have been associated with SGLT2 inhibitors as previously
mentioned.
AQ7
Evidence from pre-clinical studies supports a role for SGLT2 inhibition
and particularly ipragliflozin, in reduction of hepatic fat content and
protection from or even reversal of fibrosis [ 44, 45 ]. Activation of AMP
kinase with canagliflozin has been proposed as one of the hepatic lipid
content lowering mechanism [ 46 ]. Furthermore, ipragliflozin improved
liver biochemistry [serum alanine aminotransferase (ALT) and gamma-
glutamyltransferase (gGT) levels] in T2DM patients (n = 55), 40% of
whom had known hepatic steatosis on liver ultrasound scan at baseline,
with the effect being independent of body weight change [ 47 ]. Whether
this is an agent- rather than class-related effect is unclear. Reductions in
visceral adiposity as dictated by negative energy balance with SGLT2
inhibition are likely the main contributors. However, improved glucose
metabolism in the form of increased insulin sensitivity (discussed below)
observed with these agents, may well further prevent hepatic lipid build-
up.
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Uric Acid Levels
Reductions in serum uric acid levels have been recorded with the use of
SGLT2 inhibitors [ 12, 48, 49, 50 ]. These are usually small around 10 to
13% but the effect becomes more pronounced among patient with
hyperuricaemia at baseline. In a post hoc analysis of pooled data from four
RCTs of canagliflozin, a significantly higher percentage of patients with
hyperuricaemia at baseline reached reductions to normal serum uric acid
levels at 26 weeks of treatment [ 50 ]. Serum uric acid lowering action of
SGLT2 inhibitors is believed to be mediated by glucosuria through
modification of uric acid transport system in the renal tubule [ 51, 52 ], i.e.
solute carrier family 2, facilitated glucose transporter member 9
(SLC2A9), also known as GLUT9 which secretes urate back into the urine
in exchange for glucose [ 53, 54 ].
Glucose Metabolism
Beyond reducing blood glucose levels via enhanced urinary excretion,
SGLT2 inhibitors affect glucose metabolism by several other ways. In
diabetic obese rats, dagliflozin appeared to improve the insulin sensitivity
index (measured using a hyperglycaemic clamp) and β cell function as
assessed by disposition index, which reached the level of lean control rats
[ 55 ]. Islet morphology was also significantly improved by dapagliflozin.
In another experimental model, canagliflozin suppressed obesity-
associated inflammation in the nervous system and skeletal muscle of
obese and diabetic mice [ 56 ].
Similarly, empagliflozin reduced insulin resistance and levels of pro-
inflammatory cytokines TNF-α, IL-6 and monocyte chemoattractant
protein-1 (MCP-1); these changes were accompanied by correspondent
changes in atherosclerotic plaque size in ApoE−/− mice fed with a western
diet [ 57 ].
Furthermore, SGLT2 inhibitors are emerging as an attractive treatment
option for patients with diabetes resistant to insulin therapy due to the
presence of antibodies. Though this is a not-so-common problem in routine
clinical practice, when encountered, management is particularly
challenging. There are reports of significant improvement of glucose
metabolism with the use of SGLT2 inhibitors in such cases [ 58, 59 ].
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Among all the above, benefits in body weight and visceral adiposity have
been broadly reported with most SGLT2 inhibitors and merit particular
consideration given the high-risk metabolic profile of patients with T2DM.
Most likely, the series of these agents’ actions, discussed above, are at
least partly mediated by these two effects. Nevertheless, the clinical
significance of SGLT2 inhibitors ‘pleiotropic’ actions is yet to be
established in RCTs. Identifying diabetic subpopulations who might
receive maximal treatment benefit would be particularly important.
Renal Effect—‘Nephroprotective Effect’
Diabetic nephropathy complicates T2DM in as many as one third of cases
[ 60 ]. These patients are characterised by increased CV morbidity and
mortality [ 61 ]. SGLT2 inhibitors have been considered to have a
nephroprotective effect, which in some cases has been shown to be
independent of their hypoglycaemic action. Data suggest this effect is
evident on several aspects of kidney function and resultant from a complex
interplay of physiological mechanisms.
Proteinuria and particularly albuminuria is a hallmark of diabetic
nephropathy. Furthermore, it appears to hold a causative role in the
pathophysiology and progression of renal injury [ 62 ]. Animal studies have
shown an ameliorating effect of dapagliflozin and empagliflozin on the
progression of albuminuria principally linked to their hypoglycaemic
action [ 63, 64 ]. Consistent findings have been noted in human trials,
which, however, have suggested that these effects cannot be fully
explained by reductions in serum glucose levels and amelioration of other
metabolic parameters. On pooled data analysis, it was shown that within
24 weeks of treatment with empagliflozin, albumin to creatinine ratio
(ACR) levels were significantly reduced from baseline compared with
placebo in diabetic patients with either microalbuminuria or
macroalbuminuria (treatment difference −32%; p < 0.001 and −41%;
p < 0.01) The regression analysis models suggested that this effect cannot
be solely attributed to changes in HbA1c, body weight or BP as these
appeared to only modestly contribute [ 65 ].
Another mechanism that may account for these agents nephroprotective
effect is a reduction in glomerular hyperfiltration. The most important
evidence comes from Cherney et al. who included 40 subjects with T1DM
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in their study. Inulin and paraaminohippurate clearances were measured to
estimate GFR and effective renal plasma flow, respectively, and study
population was divided in hyperfiltration and normal filtration groups.
After 8 weeks of treatment, empagliflozin 25 mg OD was associated with
reduced GFR in the hyperfiltration patient group under both euglycaemic
and hyperglycaemic conditions. The same patient group showed an
increase in angiotensin II and aldosterone levels as well as reductions in
plasma nitric oxide (NO) and effective renal plasma flow with an increase
in renal vascular resistance both under euglycaemia and clamped
hyperglycaemia [ 66 ]. No relevant changes were detected in the group of
patients with T1DM but normal levels of GFR at baseline. The treatment
effect on glycaemic control and body weight was similar between the two
groups.
Based on the tubular hypothesis (tubuloglomerular feedback (TGF)),
chronic hyperglycaemia in diabetic patients results to increased glucose
delivery in the proximal tubule, hence, enhanced glucose reabsorption
along with sodium via the SGLT2. The juxtaglomerular apparatus
perceives this as a low-effective circulating volume condition leading to an
afferent renal vasodilatory response and, therefore, hyperfiltration [ 67 ].
NO is one of the principal mediators. It is believed that hyperfiltration
leads to glomerular injury and then, a compensatory further increase in
filtration rates in the remaining glomeruli, which will eventually result in
further glomerular loss and decline in eGFR [ 68 ]. SGLT2 inhibitors
appear to alter the TGF response by increasing sodium chloride content in
the macula densa. Given the prognostic role of hyperfiltration for
progression to chronic kidney disease (CKD) in diabetes [ 69 ], this effect
of SGLT2 inhibitors emerges as one of particular importance.
Cherney et al. emphasised in their study that the blunting effect on
hyperfiltration was most likely the result of decreased plasma NO and
effective renal plasma flow along with an increase in renal vascular
resistance as result of increased sodium chloride delivery to the distal
tubule [ 66 ].
Furthermore, the observed increase in reninaldosterone-angiotensin system
(RAAS) mediators with empaglifozin in the hyperfiltration group
represents the decrease in effective circulating volume via SGLT2
inhibitors’ mild diuretic effect. It should be noted though that plasma renin
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activity was not increased. It would be interesting to know whether there
are variations in aldosterone and angiotensin II levels related with time of
ingestion of SGLT2 inhibitor and whether these increments are clinically
meaningful.
The above observation draws attention to potential meaningful clinical
implications with combined use of RAAS and SGLT2 inhibitors resulting
in an enhanced nephroprotective effect. In a diabetic animal model,
lusegliflozin and lisinopril treatment had maximal nephroprotective effect
when compared with each monotherapy [ 70 ]. Lusegliflozin reduced the
extent of renal injury in the form of glomerular injury, fibrosis and the
presence of urinary protein casts and preserved GFR. Insulin treatment
with similar hypoglycaemic effect did not yield the same renoprotective
result. Gnudi et al. have suggested that this might be the result of the
activation of the non-classical RAAS pathway leading to the production of
angiotensin (1–7) which has a vasodilatory effect [ 71 ]. Angiotensin II
increases intraglomerular pressure through preferred vasoconstriction of
the efferent vs the afferent arteriole and hence increased filtration. RAAS
inhibition reverts this phenomenon; therefore, the combined effect of
RAAS with SGLT2 inhibitors on the kidney would be of particular
interest.
The clinical implications of the above remain to be established. Whether
this might affect progression of diabetic renal disease and effectively
reduce relevant morbidity and mortality in the long term needs to be
assessed in randomised controlled trials. Furthermore, the mechanisms
involved warrant further clarification. However, overall, it appears that the
main nephroprotective mechanism of SGLT2 inhibition is reduction in
glomerular hyperfiltration, which appears independent of glucose
lowering. Further effects appear to be the result of improved diabetes
control. The reduction on albuminuria is most likely a combination of
these two.
Beneficial Effect on Cardiovascular Outcomes
The EMPA-REG OUTCOME trial has led to a reappraisal of the
management of type 2 diabetes with hypoglycaemic medication [ 48 ]. This
was a randomized controlled trial examining the effect of empagliflozin 10
or 25 mg vs placebo on CV outcomes in a type 2 diabetic population with
established CV disease (n = 7020, >99% with established CV disease) after
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a median treatment duration of 2.6 years and a median observation period
of 3.1 years. The primary composite outcome (death from any CV causes,
non-fatal myocardial infarction and non-fatal stroke) was more frequent in
the placebo compared to empagliflozin group [12.1 vs 10.5%; hazard ratio
(HR) 0.86, 95% CI 0.74–0.99; p = 0.04]. Empagliflozin was associated
with a relative risk (RR) reduction of 38% in CV mortality (HR 0.62; 95%
CI 0.49–0.77; p < 0.001), 32% in all-cause mortality (HR 0.68; 95% CI
0.57–0.82, p < 0.001), and 35% in hospitalization for heart failure (HR
0.65; 95% CI 0.50 to 0.85; p = 0.002). The incidence of myocardial
infarction and stroke did not differ between groups. It appeared that the
beneficial effect on CV mortality was evident earlier than the effect on
primary composite end-point (i.e. CV mortality along with non-fatal
myocardial infarction and non-fatal stroke). A subsequent analysis
suggested that the composite outcome of heart failure hospitalization and
CV death was more frequent in the placebo group compared to the
empagliflozin group (8.5 vs 5.7%; HR 0.66, 95% CI 0.55–0.79; p < 0.001)
with the effect being independent of drug dose or baseline characteristics
such as age, race, eGFR and other medications. Consistently,
empagliflozin was associated with a lower frequency of hospitalization for
heart failure (2.7 vs 4.1%) as well as reduced risk for the composite
outcome of hospitalization for or death from heart failure compared with
placebo (2.8 vs. 4.5%; HR 0.61, 95% CI 0.47–0.79; p < 0.001) The benefit
of empagliflozin was observed in the whole study population, irrespective
of the presence of heart failure at baseline. Of note, pre-existing heart
failure at baseline was defined upon recorded medical history and appeared
as low as 10.1%. It may be the case that undiagnosed heart failure
(particularly diastolic dysfunction) was present in the study population.
In support of EMPA-REG study findings, the encouraging results from a
recent meta-analysis which included data from six regulatory submissions
(n = 37,525) and 57 trials (n = 33,385) regarding a total of seven agents
were published [ 72 ]. A protective CV effect associated with SGLT2
inhibition was suggested by significant reductions in the risk for major CV
events (RR 0.84, 95% CI 0.75–0.95; p = 0.006); CV death (RR 0.63, 95%
CI 0.51–0.77; p < 0.0001) and heart failure (RR 0.65, 95% CI 0.50 to 0.85;
p = 0.002). All-cause mortality was also decreased in diabetics treated with
SGLT2 inhibitors (RR 0.71 95% CI 0.61 to 0.83; p < 0·0001). However, an
increased risk of non-fatal stroke was noted in these patients (RR 1.30,
95% CI 1.00 to 1.68; p = 0.049). No difference was noted among different
27/3/2017 e.Proofing
http://eproofing.springer.com/journals/printpage.php?token=T9971nzXCFq6r3aMnv2aw3VrkHv8jW4kqN5QvEUQoPZqW3AFTHUDcg 18/31
agents with regards to their effect on CV outcomes.
Given the lack of abundance of RCTs to support an established CV benefit
from SGLT2 inhibition, these results should still be interpreted with
caution. However, a beneficial effect on CV outcomes distinguishes
SGLT2 inhibitors from other oral hypoglycaemic agents such as
thiazolidinediones and saxagliptin, which have been associated with
adverse outcomes in heart failure [ 73, 74 ]. Given the strong link between
diabetes and heart failure [ 75, 76, 77 ] which is empowered by inherent to
T2DM mechanisms further to an adverse cardiometabolic profile [ 78, 79 ].
What mechanisms underlie the CV benefit with SGLT2 inhibitors,
warrants further consideration. Improvements in classic CV risk factors
such as body weight, BP reduction, lipid profile and an overall benefit in
adverse metabolic profile common to people with T2DM may be
responsible. However, the CV benefit was evident early on during
treatment at approximately 12 weeks [ 80 ]. This suggests that more acute
effects are principally involved with haemodynamic alterations playing
possibly a key role, especially with respect to heart failure outcomes. The
most direct effect of SGLT2 inhibition is the enhanced urinary glucose and
sodium excretion; natriuresis and osmotic diuresis lead to reduction of
intravascular volume and, hence reduced pre-load. Furthermore, BP
lowering improves afterload with a further benefit from reduced arterial
stiffness associated with SGLT2 inhibition. The diuretic effect of SGLT2
inhibitors, particularly in the presence of unrecognized diastolic
dysfunction, in combination with a negative net effect on total body
sodium content, may improve CV outcome. A novel hypothesis has been
recently postulated, suggesting that SGLT2 inhibitors enhance energy
efficiency at mitochondrial level in myocardium with the utilization of β-
hydroxybutyrate as substrate [ 81, 82 ].
Whether SGLT2 inhibition affects left ventricle (LV) remodelling and
structural changes associated with heart failure, has been put forward. Data
from an experimental study reported empagliflozin treatment in diabetic
and hypertensive rats, resulted in reductions in adverse LV remodelling, as
suggested by changes in LV mass, and LV dilatation, while increased
cardiac contractility [ 83 ]. The REFORM trial a, phase IV, RCT, aims to
shed further by examining the effect of dapagliflozin on LV parameters in
patients with known heart failure [ 84 ]. In the meantime, the Dapagliflozin
Effect on CardiovascuLAR Events (DECLARE) study is examining the
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effect of SGLT2 inhibition on CV events in patients without pre-existing
macrovascular disease (i.e. primary prevention) and is due to report in
2019.
Safety Concerns
Relevant to their impact on the metabolic profile, concerns have been
raised with regards to several reports of ketoacidosis associated with
SGLT2 inhibitor use. This appears to be related to increased glucose
excretion especially in the presence of low carbohydrate diet resulting in
enhanced ketogenesis [ 85 ]. Patients with type 1 diabetes appear more
prone [ 86 ]. However, pooled data analysis of empagliflozin showed
similar rates to placebo [ 87 ]. Similarly, despite that this class of drugs
may induce a degree of volume depletion, their use has not been associated
with significantly increased rates of acute kidney injury [ 48, 88 ].
Conclusions
Remarkable findings of significant metabolic and cardioprotective effects
of SGLT2 inhibitors have emerged with a particular focus on heart failure
but the clinical significance of the above needs to be further
assessed(Table 3). In the kidney, SGLT2 inhibitors reduce hyperfiltration,
a precipitant of diabetic nephropathy. Given reported ameliorating effects
on blood pressure, central obesity and adverse lipid profile, one could
suggest that patients with the metabolic syndrome (i.e., a constellation of
the above) on top of T2DM might get maximal benefit from treatment with
SGLT2 inhibition. Prospective studies should examine whether SGLT2
inhibitors might prevent or retard the development or improve outcomes in
kidney disease. The results of their combination with RAAS inhibitors may
be of particular interest.
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